- Home
- CAPT vs OTLK Comparison
CAPT vs OTLK Comparison
Compare CAPT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPT
- OTLK
- Stock Information
- Founded
- CAPT 2005
- OTLK 2010
- Country
- CAPT South Korea
- OTLK United States
- Employees
- CAPT N/A
- OTLK N/A
- Industry
- CAPT Blank Checks
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CAPT Finance
- OTLK Health Care
- Exchange
- CAPT Nasdaq
- OTLK Nasdaq
- Market Cap
- CAPT 37.9M
- OTLK 42.8M
- IPO Year
- CAPT N/A
- OTLK 2016
- Fundamental
- Price
- CAPT $0.90
- OTLK $1.15
- Analyst Decision
- CAPT
- OTLK Buy
- Analyst Count
- CAPT 0
- OTLK 5
- Target Price
- CAPT N/A
- OTLK $5.25
- AVG Volume (30 Days)
- CAPT 158.0K
- OTLK 2.7M
- Earning Date
- CAPT 01-01-0001
- OTLK 08-14-2025
- Dividend Yield
- CAPT N/A
- OTLK N/A
- EPS Growth
- CAPT N/A
- OTLK N/A
- EPS
- CAPT N/A
- OTLK N/A
- Revenue
- CAPT $17,389,944.00
- OTLK $1,505,322.00
- Revenue This Year
- CAPT N/A
- OTLK N/A
- Revenue Next Year
- CAPT N/A
- OTLK $343.94
- P/E Ratio
- CAPT N/A
- OTLK N/A
- Revenue Growth
- CAPT 84.70
- OTLK N/A
- 52 Week Low
- CAPT $0.37
- OTLK $0.79
- 52 Week High
- CAPT $2.14
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- CAPT 40.95
- OTLK 46.22
- Support Level
- CAPT $0.83
- OTLK $1.04
- Resistance Level
- CAPT $1.05
- OTLK $1.13
- Average True Range (ATR)
- CAPT 0.06
- OTLK 0.07
- MACD
- CAPT -0.01
- OTLK 0.05
- Stochastic Oscillator
- CAPT 29.86
- OTLK 84.91
About CAPT Captivision Inc.
Captivision Inc Formerly Glaam Co Ltd is engaged in manufacturing, installing, and selling LED display G-Glass. G-Glass is an integrated ICT product that has the basic characteristics of transparent glass but can display media images at the same time. It implements media images through the glass surface while preserving the features of clear and transparent glass. G-Glass is the world's first IT building material that can be applied to various places where glass is used.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.